Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,389
datasets available to search
ShareScore release 0.9.0
Dataset results
1,389 results for “Bladder cancer”
Thulium Laser En-bloc Resection of Primary Non-muscle Invasive Bladder Cancer
ClinicalTrials.gov study NCT06818799. IPD Sharing: NO. Countries: 1. Publications: 1.
The Difference of Two Year Recurrence Rate According to Anesthetic Method During Transurethral Resection of Bladder Mass in Patients With Non-muscle Invasive Bladder Cancer: Prospective, Randomized, C
ClinicalTrials.gov study NCT03597087. IPD Sharing: NO. Countries: 1. Publications: 24.
Efficacy Study of a Urine DEK ELISA for Diagnosis of Bladder Cancer
ClinicalTrials.gov study NCT01563796. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer
ClinicalTrials.gov study NCT00406068. IPD Sharing: Not stated. Countries: 2. Publications: 1.
A Clinical Trial Aimed At Assessing the Efficacy and Safety of VT-101 for the Treatment of Non-muscle Invasive Bladder Cancer
ClinicalTrials.gov study NCT06632964. IPD Sharing: NO. Countries: 1. Publications: 9.
Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer
ClinicalTrials.gov study NCT00003105. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Adjuvant Post-radical Cystectomy Treatment for Bladder Cancer
ClinicalTrials.gov study NCT01734798. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer
ClinicalTrials.gov study NCT00033436. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
ClinicalTrials.gov study NCT03244384. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Arsenic (+3 oxidation state) methyltransferase gene polymorphisms and expression on bladder cancer
Open the record for dataset details and reuse information.
Data from: Prognostic value of ki67 in BCG-treated non-muscle invasive bladder cancer: a meta-analysis and systematic review
Objectives: The aim of this study was to explore the prognostic value of ki67 as a marker in non-muscle-invasive bladder cancer (NMIBC) patients treated with Bacillus Calmette–Guérin (BCG). Methods: Studies were systematically retrieved from the relevant databases (Web of Science, PubMed, Cochrane Library, and Embase), and the expiry date was May 2017. The research steps referred to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement. Results: A total of 11 studies that complied with the inclusion criteria were enrolled. The expression of ki67 was not statistically significantly associated with recurrence-free survival (RFS) [hazard ratio (HR): 1.331; 95% CI: 0.980–1.809)]. No significant heterogeneity was found among all included studies (I2 = 36.7%, P = 0.148). The expression of ki67 was statistically significantly associated with progression-free survival (PFS) (HR: 2.567; 95% CI: 1.562–4.219), and the overexpression of ki67 was the risk factor for PFS. Significant heterogeneity was noted among all the included studies (I2 = 55.6%, P = 0.021). The studies that might cause heterogeneity were excluded using the Galbraith plot, and then the meta-analysis was performed again. The results showed that the expression of ki67 was still associated with PFS (HR: 2.922; 95% CI: 2.002–4.266). Conclusions: The overexpression of ki67 was the risk factor for PFS, and the relationship between the expression of ki67 and RFS was not statistically significant in patients with NMIBC treated with BCG intravesical immunotherapy. Well-designed, prospective, randomized controlled trials with a large sample size are still needed to validate the findings.
Immuno-transcriptomic profiling of blood and tumor tissue identifies gene signatures associated with immunotherapy response in metastatic bladder cancer
<p>The dataset contains RNA-sequencing data (raw fastq files, not trimmed) of whole blood and whole bladder tissue samples and metadata file with sample annotation. The samples have been collected in the context of the study "Immuno-transcriptomic profiling of blood and tumor tissue identifies gene signatures associated with immunotherapy response in metastatic bladder cancer". In this study, we investigated which are the local and systemic immune changes in an experimental model of muscle-invasive bladder cancer upon immunotherapy. The RNA-sequencing data have been used to produce the results presented in the study. Please refer to the study publication material and methods and the metadata file for details.</p>
raw data - Bioinformatics analysis reveals the m5C-associated gene DLGAP5 as a prognostic and immunological marker in bladder cancer
Open the record for dataset details and reuse information.
A multi-center MRI dataset for bladder cancer and baseline evaluations of federated learning in its clinical application
Open the record for dataset details and reuse information.
The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder Cancer
ClinicalTrials.gov study NCT03577132. IPD Sharing: NO. Countries: 0. Publications: 6.
FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer
ClinicalTrials.gov study NCT06421142. IPD Sharing: NO. Countries: 1. Publications: 0.
The Personal Patient Profile Decision Support for Patients With Bladder Cancer
ClinicalTrials.gov study NCT05033067. IPD Sharing: YES. Countries: 1. Publications: 0.
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
ClinicalTrials.gov study NCT02010203. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer
ClinicalTrials.gov study NCT04386746. IPD Sharing: NO. Countries: 1. Publications: 0.
Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
ClinicalTrials.gov study NCT03558087. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.